Compare NRG Energy Inc (NRG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs State Street SPDR S&P Biotech ETF — how do they compare? NRG Energy Inc trades at $120.97 (market cap $24.83B), while State Street SPDR S&P Biotech ETF trades at $159.4. The key difference: NRG Energy Inc pays a 1.61% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, NRG Energy Inc nearer its low. Which is the better fit depends on your goals.
| NRG | XBI | |
|---|---|---|
Market Cap | $24.83B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $184.03 | $164.28 |
52-Week Low | $117.04 | $86.92 |
Enterprise Value | $48.79B | — |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $120.37, down 1.23% with a bearish technical signal. Recent Q2 2026 earnings missed estimates at $1.49 EPS versus $1.69 expected, though revenue grew 11% year-over-year. The company is advancing a 1.2 GW Texas data-center power project to capitalize on AI-driven electricity demand, supported by a 69% analyst buy rating and a $207.83 consensus price target. Cash flow from operations was $1.91B in 2025, but net income margin compressed to 2.56%.
Outlook is mixed: growth initiatives in data center power present upside, but execution risks and rising interest costs pressure margins. The stock offers a 1.6% dividend yield, yet high debt-to-asset ratio of 56.42% in 2025 warrants caution. Near-term support lies at $119, with resistance at $122.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
